Tips+Tools

The next major advance in simplification of treatment could be the approval of antiretrovirals in nanosuspension formulations that release drug molecules slowly, and thus may enable once-monthly'or even less frequent'injectable antiretroviral therapy. A Tibotec Therapeutics experimental nonnuke, rilpivirine (TMC278), is the compound furthest along in the development of this technology, according to research released at the 15th Conference on Retroviruses and Opportunistic Infections.